Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).

Low-level silica exposure ups overall, cause-specific mortality risk

18 Sep 2017

Low-level occupational exposure to crystalline silica is associated with increased risk of mortality from respiratory diseases, pulmonary heart disease, lung cancer and ischaemic heart disease, among other complications, a new study has found.

The study included 44,087 Chinese workers (81.2 percent male) with histories of at least 1 year of pottery factory or metal mine work. Of these, 24,731 had never been exposed to silica and 20,076 had had a lifetime peak silica exposure of 0.35 mg/m3.

Participants who had ever been exposed to crystalline silica were further categorized into two according to the lifetime highest exposure: those with a lifetime peak exposure of ≤0.05 mg/m3 (n=4,038) and those with ≤0.10 mg/m3 (n=10,486).

Of participants in the ≤0.10 mg/m3 level, quartiles of silica exposure showed a significant and positive linear trend with overall mortality risk (hazard ratios [HRs] per quartile, 1.11, 1.23, 1.33 and 1.18; p<0.001 for linear trend).

Silica exposure also correlated significantly with higher mortality risks from malignant neoplasms (HR, 1.06; 95 percent CI, 1.03 to 1.09), lung cancer (HR, 1.08; 1.02 to 1.14), ischaemic heart disease (HR, 1.09; 1.02 to 1.16), pulmonary heart disease (HR, 1.08; 1.00 to 1.16) and respiratory disease (HR, 1.20; 1.14 to 1.26).

Trends were similar in the ≤0.05 and ≤0.35 mg/m3 level.

Over the follow-up period of 33.5 years, 8,506 all-cause deaths were reported, yielding an overall mortality rate of 594.0 per 100,000 person-years. The mortality rate for the group never exposed to silica was 550.7 per 100,000 person-years, while for those with a lifetime peak exposure of ≤0.35 mg/m3, the rate was 643.4 per 100,000 person-years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Alexander Drilon, 19 Jul 2017
With the dramatic evolution of sequencing technology and emergence of effective targeted therapies, using a comprehensive molecular approach to guide treatment decisions is becoming more accessible and applicable in the clinic. At the recent Foundation Medicine meeting in Hong Kong, Dr Alexander Drilon, clinical director of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSKCC), New York, US, discussed the current landscape and potential benefits of comprehensive molecular profiling in non-small cell lung cancer (NSCLC).